《Nature,4月23日,Obesity and impaired metabolic health in patients with COVID-19》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-04-24
  • Obesity and impaired metabolic health in patients with COVID-19

    Norbert Stefan, Andreas L. Birkenfeld, Matthias B. Schulze & David S. Ludwig

    Nature Reviews Endocrinology (2020)

    Preliminary data suggest that people with obesity are at increased risk of severe COVID-19. However, as data on metabolic parameters (such as BMI and levels of glucose and insulin) in patients with COVID-19 are scarce, increased reporting is needed to improve our understanding of COVID-19 and the care of affected patients.

    In China, older age (≥65 years) and the presence of comorbidities are associated with a more severe course of COVID-19 in patients infected with the novel coronavirus (SARS-CoV-2). Among the comorbid conditions, the highest fatality rate was found for cardiovascular disease (CVD) (10.5%) and diabetes mellitus (7.3%), followed by chronic respiratory diseases (6.3%), hypertension (6.0%) and cancer (5.6%)1. A direct endocrine and metabolic link between hypertension and diabetes mellitus and coronavirus infection, which might involve angiotensin-converting enzyme 2, is being discussed2.

  • 原文来源:https://www.nature.com/articles/s41574-020-0364-6
相关报告
  • 《Nature,4月23日,Complement as a target in COVID-19?》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-24
    • Complement as a target in COVID-19? Antonio M. Risitano, Dimitrios C. Mastellos, Markus Huber-Lang, Despina Yancopoulou, Cecilia Garlanda, Fabio Ciceri & John D. Lambris Nature Reviews Immunology (2020) There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients. Most patients who become critically ill following infection with SARS-CoV-2, the causative agent of COVID-19, develop acute respiratory distress syndrome (ARDS)1. The deterioration of lung function has been attributed to a maladaptive immune response rather than increased viral loads. One theory is that the activation of lung-resident immune cells via pattern-recognition receptors drives the release of pro-inflammatory cytokines and extravasation of blood neutrophils and monocytes into the bronchi. These cells may disrupt the air–blood barrier by causing collateral tissue damage, particularly to airway epithelial cells and vascular endothelial cells, which express the ACE2 entry receptor for SARS-CoV-2; the damage of vascular endothelial cells may account for thrombotic microangiopathies.
  • 《Nature,3月19日,Functional exhaustion of antiviral lymphocytes in COVID-19 patients》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-20
    • Functional exhaustion of antiviral lymphocytes in COVID-19 patients Meijuan Zheng, Yong Gao, Gang Wang, Guobin Song, Siyu Liu, Dandan Sun, Yuanhong Xu & Zhigang Tian Cellular & Molecular Immunology (2020) In December 2019, a novel coronavirus was first reported in Wuhan, China.1 It was named by the World Health Organization as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is responsible for coronavirus disease 2019 (COVID-19). Up to 28 February 2020, 79,394 cases have been confirmed according to China’s National Health Commission. Outside China, the virus has spread rapidly to over 36 countries and territories.